Boehringer Ingelheim to unveil oncology research at WCLC
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Search
U.S. FDA grants Breakthrough Therapy designation for MASH
Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
What our partners say
What our partners say
Bringing Value to the Healthcare Community
Our fundamental mission is to make the lives of patients better.
Cognitive Impairment with Schizophrenia
live_well_with_gpp_infographic.pdf
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Your Guide to Partnering with Us
Your Guide to Partnering with Us
Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia
Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia
Biosimilars
Biosimilars
IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US
BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.
AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
A Unique Bond: human and animal health
A Unique Bond: human and animal health
Human Health Innovation
Pipeline
Companion Animals & Horses
Companion Animals & Horses
FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US
FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.
Schizophrenia in real life: Stories of resilience and hope
Discover the reality of life with schizophrenia through the stories of four people who are breaking down the stigma of living with a serious mental illness.
Recognizing Parents Supporting Other Parents
Recognizing Parents Supporting Other Parents
Sustainable Development - Our Commitment
Our Commitment
Borderline Personality Disorder
Borderline Personality Disorder
Depression
Depression
Update on LUME-Meso Clinical Trial
Click here to read an update on the LUME-Meso clinical trial, comparing nintedanib with other treatment options for malignant pleural mesothelioma.
Interchangeable Biosimilar Now on Express Scripts® Formulary
Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.